Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Video content above is prompted by the following:
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.